The UC Davis Comprehensive Cancer Center has been awarded the National Clinical Trials Network - Lead Academic Participating Sites (LAPS) UG1 grant – the only center in California to do so. The National Cancer Institute (NCI) grant, $500,000 per year for six years, supports the management of several kinds of multi-center, NCI-sponsored trials to benefit patients of all ages and with different cancer types.
David Gandara, a Cancer Center senior advisor, lung cancer specialist and co-principal investigator on the LAPS grant, said the successful renewal of the LAPS grant means that UC Davis is a lead academic participating site for clinical trials through the NCI across cooperative trials groups. He noted that three other leading California cancer centers lost their LAPS grant in this funding round.
“It’s recognition,” he said. “A good housekeeping seal of approval.”
LAPS unites four major clinical trials networks. Patients who receive care at a LAPS grant site have access to an array of clinical studies, including MATCH, a precision medicine trial in which patients receive treatment based on the genetic changes found in their tumors. It also includes Lung MAP, another a precision medicine clinical trial for people with advanced non-small cell lung cancer that has continued to grow after treatment.
Co-principal investigator Richard Valicenti, chair of the Department of Radiation Oncology, said the LAPS grant “puts us in a leadership position in terms of clinical trial accrual, clinical trial development and career development for junior faculty. And it gets our people at the table of national cancer committees.”